3-drug regimen lowers HbA1C, treatment failure in new-onset diabetes

10/8/2013 | InternalMedicineNews.com (free registration)

Patients with new-onset type 2 diabetes who had initial triple-drug treatment of metformin, exenatide and pioglitazone attained a mean HbA1C of 5.9% at two years, compared with 6.6% in those who received conventional stepwise treatment, a study indicated. Researchers also found the triple-drug regimen was associated with an 84% reduction in two-year treatment failure rates compared with standard therapy. The results were presented at the European Association for the Study of Diabetes meeting.

View Full Article in:

InternalMedicineNews.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC